Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

ng process scale-up efforts, increased personnel related costs to support these efforts, and increased share-based compensation costs.

On January 1, 2006, Alexza adopted FAS 123R and reports employee share-based compensation expense based on the fair value of the award. Share-based compensation was $1,191,000 in the first quarter of 2008 compared to $719,000 in the comparable period in 2007.

Alexza's Consolidated Statements of Operations include the operations of Symphony Allegro, Inc., its variable interest entity. As the Company has no direct ownership in Allegro, it reduces its net loss by the losses incurred by Allegro. "Loss attributed to noncontrolling interest in Symphony Allegro, Inc." reduced net loss for the first quarter of 2008 by $3.8 million and reduced net loss for the first quarter of 2007 by $2.1 million.

Product Candidates Development Update

-- AZ-004 (Staccato loxapine). Alexza is developing AZ-004 for the

treatment of acute agitation in patients with schizophrenia or bipolar

disorder. In February 2008, Alexza initiated its first Phase 3

clinical trial, designed to enroll approximately 300 schizophrenic

patients with acute agitation at 25 U.S. clinical centers. The trial

is an in-clinic, multi-center, randomized, double-blind,

placebo-controlled study and will test AZ-004 at two dose levels, 5

and 10 mg. Patients may receive up to 3 doses of study drug in a

24-hour period, depending on their clinical status. The primary

endpoint for the study is the change from baseline in the PEC score,

measured at 2 hours after the first dose. Various assessments of a

patient's agitation state will be conducted at serial time points

using standard agitation scales over the first 4-hour post-dose time

period, with follow-up assessments at the end of the 24-hour study

period. Side effe
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences company ... advanced microarray diagnostics, today announced it will hold an ... pm ET.  During the call, ... of SQI,s recent commercialization progress and then introduce Dr. ... appointed to the Board of Directors of SQI and ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
(Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
(Date:8/15/2014)... FOREST, Ill. , Aug. 15, 2014   ... world,s leading provider of injectable drugs and infusion technologies, ... Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 9, ... The presentation is scheduled to begin at 11:45 ... will be available to all interested parties through a ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... when theoretical work is eventually supported by experimentation. Such ... Italian and US scientists when they received preliminary confirmation ... that is currently orbiting the Earth on the Foton-M3 ... week ago, the scientists are already very excited about ...
... Board Reflects Emphasis on Drug Development and Recent ... ... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced several changes to ... drug development and the completion of a major strategic financing,with ...
... NanoBio(R) Corporation, a,biopharmaceutical company developing novel anti-infective ... infections, today announced,the addition of four new scientists ... PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, ... developing and commercializing,its novel topical anti-infectives and mucosal ...
Cached Biology Technology:Fluid theory confirmed by Foton 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 3Lexicon Appoints Judith Swain, M.D. to Board of Directors 4NanoBio Expands Drug Development Team for Its Anti-Infective Products 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 3
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... is available in German . ... intermittent energy sources. If a large amount of electricity is ... excess energy will have to be stored during productive periods ... storage capacities are far from adequate for the purpose. Science ... important focus lies on battery systems that used to be ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... by global warming can prove extremely destructive to island habitats, ... C. Bellard, C. Leclerc and F. Courchamp of the ... possible scenarios, from optimistic to very pessimistic, to bring attention ... biodiversity hotspots worldwide. The study was published in the open ...
... measures carbon dioxide and suggests that far from being a ... a biological signalling molecule. Researchers led by Professor Nick ... of Warwick have shown that the body senses carbon dioxide ... receptor for the gas. Connexin 26 is better known as ...
... largest lake in Britain and Ireland, Lough Neagh, has lost ... to researchers at Queen,s University Belfast., The study by Quercus, ... number of diving ducks migrating to the lake for the ... in the space of a decade., The research, published in ...
Cached Biology News:Island biodiversity in danger of total submersion with climate change 2Carbon dioxide's new-found signalling role could be applied to blood flow, birth and deafness 2Largest lake in Britain and Ireland has lost three-quarters of winter water birds 2
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
...
in vitro Translation, Accessory Products...
... The GenoStat Inducible Expression System provides tightly ... mammalian cells and is capable of repeated ... is mediated by the highly specific interaction ... bipartite nuclear receptor complex. Gene expression levels ...
Biology Products: